In obese patients, should intravenous acyclovir be dosed based on actual body weight or adjusted body weight?

Intravenous Acyclovir Dosing in Obese Patients

In obese patients, intravenous acyclovir should be dosed using ideal body weight (IBW), as explicitly recommended by the FDA drug label, with consideration that adjusted body weight (AdjBW) may provide better pharmacokinetic exposure while maintaining acceptable safety. 1

Primary Recommendation: FDA-Approved Dosing Strategy

The FDA drug label for intravenous acyclovir explicitly states: "Obese patients should be dosed at the recommended adult dose using Ideal Body Weight." 1 This is the official, regulatory-approved dosing strategy and should serve as the baseline approach.

The Clinical Dilemma: Safety vs. Efficacy Trade-offs

However, recent high-quality evidence reveals a more nuanced picture that challenges simple adherence to IBW dosing:

Safety Profile (Acute Kidney Injury Risk)

The most recent and highest quality study (2025) demonstrates that IBW dosing has the lowest risk of acute kidney injury among all dosing strategies. 2 In this retrospective cohort of 339 obese patients:

• AKI occurred in 17.3% with TBW dosing, 11.6% with AdjBW dosing, and only 7% with IBW dosing
• IBW dosing showed significantly lower odds of AKI compared to TBW (adjusted OR 0.27,95% CI 0.08-0.85)
• Combined reduced dosing (AdjBW or IBW) was associated with fewer AKI events (adjusted OR 0.39,95% CI 0.19-0.82) 2

A 2023 study corroborates these safety findings, showing no patients developed AKI with AdjBW dosing compared to 13.1% with IBW dosing, though this counterintuitive finding may reflect the overall low AKI rate (8.5%) in their cohort. 3

Pharmacokinetic Considerations (Efficacy Concerns)

The critical caveat: IBW dosing leads to subtherapeutic drug exposure in obese patients. A 2016 prospective pharmacokinetic study demonstrated that when obese patients receive acyclovir dosed by IBW (per FDA recommendations), they achieve: 4

• Significantly lower AUC (15.2 vs 24.0 mg·h/L, P=0.011)
• Lower peak concentrations (5.8 vs 8.2 mg/L, P=0.031)
• Higher systemic clearance (19.4 vs 14.3 L/h, P=0.047) compared to normal-weight patients dosed by TBW

The authors concluded that adjusted body weight dosing would more closely approximate the exposure seen in normal-weight patients. 4

Practical Dosing Algorithm

For most obese patients requiring IV acyclovir:

1. Start with IBW dosing as per FDA recommendations 1
2. Monitor renal function closely (baseline and every 24-48 hours during therapy)
3. Consider AdjBW dosing in specific scenarios:
   • Severe, life-threatening infections (e.g., herpes encephalitis)
   • Immunocompromised patients where therapeutic failure has high morbidity
   • Patients with normal baseline renal function and adequate hydration
   • When therapeutic drug monitoring is available

Adjusted Body Weight Calculation:

• AdjBW = IBW + 0.4 × (TBW - IBW)

Critical Pitfalls to Avoid

• Never use total body weight for dosing - this substantially increases nephrotoxicity risk (17.3% AKI rate) without proven efficacy benefit 2
• Do not overlook "overweight" patients - even patients with BMI 25-30 kg/m² are at risk when dosed by actual weight rather than IBW 5
• Ensure adequate hydration - acyclovir crystallizes in renal tubules; maintain urine output and consider pre-hydration
• Avoid rapid infusion - always infuse over 1 hour minimum to reduce nephrotoxicity risk 1

Special Populations

For herpes encephalitis specifically (where underdosing has catastrophic consequences):

• Standard adult dose is 10 mg/kg every 8 hours 1
• Consider AdjBW in obese patients given the severity of infection
• A 2017 survey revealed significant practice variability, with most pharmacists using AdjBW for morbidly obese patients 6

Monitoring Parameters

• Baseline and serial serum creatinine (every 24-48 hours)
• Urine output (maintain adequate hydration)
• Neurological status (acyclovir neurotoxicity presents as confusion, hallucinations, seizures)
• Consider therapeutic drug monitoring if available, particularly when using AdjBW dosing

Bottom Line

The safest approach is IBW dosing per FDA guidance 1, which minimizes nephrotoxicity risk 2. However, clinicians must recognize this creates a therapeutic compromise—lower drug exposure that may be suboptimal for severe infections 4. For life-threatening infections in patients with normal renal function, AdjBW represents a reasonable middle ground that balances efficacy and safety 2, 3, though this requires heightened renal monitoring.